These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29693877)

  • 21. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
    Shawky H; Tawfik H; Hewidy M
    J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
    Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
    Vergote I; Armstrong D; Scambia G; Teneriello M; Sehouli J; Schweizer C; Weil SC; Bamias A; Fujiwara K; Ochiai K; Poole C; Gorbunova V; Wang W; O'Shannessy D; Herzog TJ
    J Clin Oncol; 2016 Jul; 34(19):2271-8. PubMed ID: 27001568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.
    Pirolli R; de Alencar VTL; Estati FL; Ribeiro ARG; Honda DYT; de Oliveira M; da Silveira Nogueira Lima JP; Dos Santos ES; Guimarães APG; Baiocchi G; da Costa AABA
    BMC Cancer; 2021 May; 21(1):525. PubMed ID: 33964923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
    Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
    Liu JF; Ray-Coquard I; Selle F; Poveda AM; Cibula D; Hirte H; Hilpert F; Raspagliesi F; Gladieff L; Harter P; Siena S; Del Campo JM; Tabah-Fisch I; Pearlberg J; Moyo V; Riahi K; Nering R; Kubasek W; Adiwijaya B; Czibere A; Naumann RW; Coleman RL; Vergote I; MacBeath G; Pujade-Lauraine E
    J Clin Oncol; 2016 Dec; 34(36):4345-4353. PubMed ID: 27998236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).
    Lortholary A; Largillier R; Weber B; Gladieff L; Alexandre J; Durando X; Slama B; Dauba J; Paraiso D; Pujade-Lauraine E;
    Ann Oncol; 2012 Feb; 23(2):346-52. PubMed ID: 21562072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
    Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.
    Banerjee S; Rustin G; Paul J; Williams C; Pledge S; Gabra H; Skailes G; Lamont A; Hindley A; Goss G; Gilby E; Hogg M; Harper P; Kipps E; Lewsley LA; Hall M; Vasey P; Kaye SB
    Ann Oncol; 2013 Mar; 24(3):679-87. PubMed ID: 23041585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
    Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
    J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
    Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
    BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
    Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
    Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
    Huang CY; Yang YC; Wang KL; Chen TC; Chen JR; Weng CS; Chien HJ; Chang CL
    Taiwan J Obstet Gynecol; 2016 Jun; 55(3):405-9. PubMed ID: 27343324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
    Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
    Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
    Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
    Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Dickinson HO
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.